457 related articles for article (PubMed ID: 16636335)
1. Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer.
Pierce LJ; Levin AM; Rebbeck TR; Ben-David MA; Friedman E; Solin LJ; Harris EE; Gaffney DK; Haffty BG; Dawson LA; Narod SA; Olivotto IA; Eisen A; Whelan TJ; Olopade OI; Isaacs C; Merajver SD; Wong JS; Garber JE; Weber BL
J Clin Oncol; 2006 Jun; 24(16):2437-43. PubMed ID: 16636335
[TBL] [Abstract][Full Text] [Related]
2. Breast-conserving surgery in BRCA1/2 mutation carriers: are we approaching an answer?
Garcia-Etienne CA; Barile M; Gentilini OD; Botteri E; Rotmensz N; Sagona A; Farante G; Galimberti V; Luini A; Veronesi P; Bonanni B
Ann Surg Oncol; 2009 Dec; 16(12):3380-7. PubMed ID: 19649554
[TBL] [Abstract][Full Text] [Related]
3. Is the breast-conserving treatment with radiotherapy appropriate in BRCA1/2 mutation carriers? Long-term results and review of the literature.
Kirova YM; Savignoni A; Sigal-Zafrani B; de La Rochefordiere A; Salmon RJ; This P; Asselain B; Stoppa-Lyonnet D; Fourquet A
Breast Cancer Res Treat; 2010 Feb; 120(1):119-26. PubMed ID: 20033769
[TBL] [Abstract][Full Text] [Related]
4. Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy.
Kirova YM; Stoppa-Lyonnet D; Savignoni A; Sigal-Zafrani B; Fabre N; Fourquet A;
Eur J Cancer; 2005 Oct; 41(15):2304-11. PubMed ID: 16140006
[TBL] [Abstract][Full Text] [Related]
5. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.
Metcalfe K; Lynch HT; Ghadirian P; Tung N; Olivotto I; Warner E; Olopade OI; Eisen A; Weber B; McLennan J; Sun P; Foulkes WD; Narod SA
J Clin Oncol; 2004 Jun; 22(12):2328-35. PubMed ID: 15197194
[TBL] [Abstract][Full Text] [Related]
6. Improving local control with breast-conserving therapy: a 27-year single-institution experience.
Cabioglu N; Hunt KK; Buchholz TA; Mirza N; Singletary SE; Kuerer HM; Babiera GV; Ames FC; Sahin AA; Meric-Bernstam F
Cancer; 2005 Jul; 104(1):20-9. PubMed ID: 15912514
[TBL] [Abstract][Full Text] [Related]
7. Ipsilateral breast tumour recurrence in hereditary breast cancer following breast-conserving therapy.
Seynaeve C; Verhoog LC; van de Bosch LM; van Geel AN; Menke-Pluymers M; Meijers-Heijboer EJ; van den Ouweland AM; Wagner A; Creutzberg CL; Niermeijer MF; Klijn JG; Brekelmans CT
Eur J Cancer; 2004 May; 40(8):1150-8. PubMed ID: 15110878
[TBL] [Abstract][Full Text] [Related]
8. Contralateral recurrence and prognostic factors in familial non-BRCA1/2-associated breast cancer.
Tilanus-Linthorst MM; Alves C; Seynaeve C; Menke-Pluymers MB; Eggermont AM; Brekelmans CT
Br J Surg; 2006 Aug; 93(8):961-8. PubMed ID: 16758466
[TBL] [Abstract][Full Text] [Related]
9. Effect of margins on ipsilateral breast tumor recurrence after breast conservation therapy for lymph node-negative breast carcinoma.
Leong C; Boyages J; Jayasinghe UW; Bilous M; Ung O; Chua B; Salisbury E; Wong AY
Cancer; 2004 May; 100(9):1823-32. PubMed ID: 15112262
[TBL] [Abstract][Full Text] [Related]
10. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations.
Rebbeck TR; Lynch HT; Neuhausen SL; Narod SA; Van't Veer L; Garber JE; Evans G; Isaacs C; Daly MB; Matloff E; Olopade OI; Weber BL;
N Engl J Med; 2002 May; 346(21):1616-22. PubMed ID: 12023993
[TBL] [Abstract][Full Text] [Related]
11. Breast cancer prognosis in BRCA1 and BRCA2 mutation carriers: an International Prospective Breast Cancer Family Registry population-based cohort study.
Goodwin PJ; Phillips KA; West DW; Ennis M; Hopper JL; John EM; O'Malley FP; Milne RL; Andrulis IL; Friedlander ML; Southey MC; Apicella C; Giles GG; Longacre TA
J Clin Oncol; 2012 Jan; 30(1):19-26. PubMed ID: 22147742
[TBL] [Abstract][Full Text] [Related]
12. The impact of radiotherapy on the incidence and time of occurrence of local recurrence in early-stage breast cancer after breast conserving therapy.
Fodor J; Major T; Polgár C; Tóth J; Németh G
Neoplasma; 2000; 47(3):181-6. PubMed ID: 11043843
[TBL] [Abstract][Full Text] [Related]
13. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.
Rebbeck TR; Friebel T; Lynch HT; Neuhausen SL; van 't Veer L; Garber JE; Evans GR; Narod SA; Isaacs C; Matloff E; Daly MB; Olopade OI; Weber BL
J Clin Oncol; 2004 Mar; 22(6):1055-62. PubMed ID: 14981104
[TBL] [Abstract][Full Text] [Related]
14. Factors predicting in-breast tumor recurrence after breast-conserving surgery.
Mechera R; Viehl CT; Oertli D
Breast Cancer Res Treat; 2009 Jul; 116(1):171-7. PubMed ID: 18815880
[TBL] [Abstract][Full Text] [Related]
15. Breast-feeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.
Jernström H; Lubinski J; Lynch HT; Ghadirian P; Neuhausen S; Isaacs C; Weber BL; Horsman D; Rosen B; Foulkes WD; Friedman E; Gershoni-Baruch R; Ainsworth P; Daly M; Garber J; Olsson H; Sun P; Narod SA
J Natl Cancer Inst; 2004 Jul; 96(14):1094-8. PubMed ID: 15265971
[TBL] [Abstract][Full Text] [Related]
16. Changes in temporal patterns of local failure after breast-conserving therapy and their prognostic implications.
Krauss DJ; Kestin LL; Mitchell C; Martinez AA; Vicini FA
Int J Radiat Oncol Biol Phys; 2004 Nov; 60(3):731-40. PubMed ID: 15465189
[TBL] [Abstract][Full Text] [Related]
17. Radiotherapy for breast cancer in BRCA1/BRCA2 carriers: clinical issues and management dilemmas.
Pierce L
Semin Radiat Oncol; 2002 Oct; 12(4):352-61. PubMed ID: 12382193
[TBL] [Abstract][Full Text] [Related]
18. Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation.
Meijers-Heijboer H; Brekelmans CT; Menke-Pluymers M; Seynaeve C; Baalbergen A; Burger C; Crepin E; van den Ouweland AW; van Geel B; Klijn JG
J Clin Oncol; 2003 May; 21(9):1675-81. PubMed ID: 12721241
[TBL] [Abstract][Full Text] [Related]
19. Contralateral risk-reducing mastectomy in BRCA1 and BRCA2 mutation carriers and other high-risk women in the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab).
Kiely BE; Jenkins MA; McKinley JM; Friedlander ML; Weideman P; Milne RL; McLachlan SA; Hopper JL; Phillips KA
Breast Cancer Res Treat; 2010 Apr; 120(3):715-23. PubMed ID: 19669874
[TBL] [Abstract][Full Text] [Related]
20. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
